Home・Aktien・Coherus Oncology Inc

Coherus Oncology Inc

Open

BrancheGesundheitswesen

1.35 -2.88

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.34

Max

1.4

Schlüsselkennzahlen
By Trading Economics
Einkommen	-21M -59M
Verkäufe	2M 14M
KGV Branchendurchschnitt	3.509 57.371
EPS	-0.22
Gewinnspanne	-412.092
Angestellte	144
EBITDA	3.7M -30M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+469.85% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-44M 178M
Vorheriger Eröffnungskurs	4.23
Vorheriger Schlusskurs	1.35

Nachrichtenstimmung

By Acuity

80%

20%

317 / 340 Ranking in Healthcare

Coherus Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 20:04 UTC

Coherus Oncology Inc shares are lower today, continuing a broader market decline. No specific company news has been identified to explain the movement.

21. Aug. 2026, 20:01 UTC

Correlated Moves

Coherus BioSciences Inc. shares are higher today, reflecting positive momentum in the biotechnology sector and broader trends in related equities since Thursday's close.

20. Aug. 2026, 23:16 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting modest gains despite broader market pressures and no specific company news identified.

19. Aug. 2026, 20:02 UTC

Coherus BioSciences remains roughly flat during Wednesday's session, with no specific news identified. The broader market also showed little change.

18. Aug. 2026, 23:26 UTC

Coherus BioSciences Inc is trading higher in after-market hours, despite broader market pressures from rising bond yields and elevated oil prices.

17. Aug. 2026, 23:41 UTC

News

Coherus BioSciences announced a special dividend of contingent value rights, boosting shares in after-market trading following the company's strategic asset sale initiative.

14. Aug. 2026, 19:31 UTC

Coherus BioSciences Inc shares are higher today, despite no specific news. Broader market sentiment includes concerns over disappointing U.S. retail sales data.

13. Aug. 2026, 19:46 UTC

Social Media

Coherus BioSciences Inc shares are lower, extending a four-session decline. Despite social media optimism, the stock remains below its 20-day moving average.

12. Aug. 2026, 23:01 UTC

Coherus BioSciences Inc shares are trading higher in after-market hours, despite recent declines and no specific news to explain the movement.

11. Aug. 2026, 19:36 UTC

Coherus BioSciences Inc shares are lower amid broader market sentiment influenced by geopolitical tensions and upcoming U.S. inflation reports. No specific company news identified.

10. Aug. 2026, 23:31 UTC

Coherus BioSciences Inc shares are higher in after-market trading, advancing from a low of 0.81% to a high of 3.25% since Monday's close.

8. Aug. 2026, 00:01 UTC

Coherus BioSciences Inc shares rose in after-market hours, recovering from earlier volatility and settling higher since Friday's close despite no specific news identified.

7. Aug. 2026, 23:21 UTC

Coherus BioSciences Inc shares are rising in after-market trading, following a Labor Department report that reduced expectations for a Federal Reserve rate hike.

6. Aug. 2026, 23:21 UTC

Coherus BioSciences Inc shares fell in after-market trading, reflecting ongoing weakness and volatility amid a lack of specific news to explain the decline.

5. Aug. 2026, 23:01 UTC

News

Coherus BioSciences shares are lower in after-market trading following a second-quarter adjusted EPS of -$0.19, despite exceeding estimates. Sales missed expectations at $14.31 million.

4. Aug. 2026, 23:56 UTC

Coherus BioSciences Inc shares are higher in after-market hours, reflecting strong demand since Tuesday's close amid a narrowing U.S. trade deficit.

3. Aug. 2026, 19:44 UTC

Coherus BioSciences Inc shares are higher during Monday's session, continuing a notable advance since Friday's close, despite trading below its 20-day moving average.

31. Juli 2026, 20:06 UTC

Coherus BioSciences shares are lower today, amid rising U.S. Treasury yields and crude oil prices, which have heightened inflation concerns and interest rate expectations.

30. Juli 2026, 22:46 UTC

Coherus BioSciences Inc shares are higher in after-market trading, reflecting a positive response amid broader market recovery despite no specific company news identified.

29. Juli 2026, 18:46 UTC

Macro Event

Coherus BioSciences Inc shares are lower today amid market volatility following the Federal Reserve's decision to maintain interest rates steady.

27. Juli 2026, 17:31 UTC

Coherus BioSciences Inc shares are higher during Monday's session, reflecting broader market trends amid declining oil prices that have eased inflation concerns.

23. Juli 2026, 19:56 UTC

Coherus BioSciences Inc is trading lower amid broader market concerns over corporate earnings and inflation pressures. Shares remain below their 20-day moving average.

22. Juli 2026, 18:26 UTC

Coherus BioSciences Inc shares are trading lower amid broader market pressures, remaining near the lower end of their one-month range. No specific news was identified.

21. Juli 2026, 19:41 UTC

Social Media

Coherus BioSciences Inc shares are higher as analysts set a $7 average price target, with potential for positive data readouts this month.

20. Juli 2026, 17:31 UTC

Coherus BioSciences Inc. shares are roughly flat today, showing little change since Friday's close amid routine trading activity within a one-month range.

Peer-Vergleich

Kursveränderung

Coherus Oncology Inc Prognose

Kursziel

By TipRanks

469.85% Vorteil

12-Monats-Prognose

Durchschnitt 7.75 USD 469.85%

Hoch 10 USD

Tief 4 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Coherus Oncology Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Coherus Oncology Inc – Dist abgegeben haben.

Stimmung

By Acuity

317 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.